Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESTRO 2022 | Investigating the incidence and outcomes of patients with oligometastatic esophagogastric cancer

Tiuri Kroese • 16 May 2022
ESTRO 2022
Gastroesophageal Cancer

Tiuri Kroese, MD, University Medical Center Utrecht, Utrecht, Netherlands, discusses the rationale behind a multicenter study investigating the incidence and outcomes of patients with oligometastatic esophagogastric cancer. This interview took place at the European Society for Radiotherapy and Oncology (ESTRO) 2022 annual congress in Copenhagen, Denmark, and online.

More from Tiuri Kroese

0:50
Next steps for improving outcomes for patients with oligometastatic esophagogastric cancer
Tiuri Kroese • 16 May 2022
2:10
Retrospective analysis of incidence/outcomes of patients with oligometastatic esophagogastric cancer
Tiuri Kroese • 16 May 2022

Related Videos

0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
2:11
COMPASSION-15: cadonilimab in advanced gastric cancers
Yelena Janjigian • 8 Apr 2024
1:28
Evolving biomarker driven therapies to overcome gastric cancer tumor resistance
Yelena Janjigian • 8 Apr 2024
3:34
FLOW + SPOTLIGHT: addressing nausea + vomiting in gastric cancer treatment with 1L zolbetuximab
Kohei Shitara • 19 Jan 2024
The content of VJOncology is intended for healthcare professionals